NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
SKIN
SkinHealth Systems Inc.
SKIN has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SKIN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Strong |
SKIN's balance sheet is currently strong, and its revenue, profitability and cash flow are stable.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SKIN PE Valuation
SKIN has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SKIN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect SKIN's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SKIN in the latest year-over-year earnings comparison.
SKIN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.94 | +$2.12 |
| Q2 2026 | -$3.60 | +$1.66 |
| Q1 2026 | -$2.60 | +$5.26 |
SKIN is still losing money, but far less than before: $1.94 per share over the past year, against $99.60 at its worst in early 2022.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over SKIN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SKIN on profitability, with a higher operating margin.
SKIN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $69.2M | -2.1% |
| Q2 2026 | $72.1M | -7.8% |
| Q1 2026 | $64.9M | -6.7% |
| Q4 2025 | $82.4M | -1.3% |
| Q3 2025 | $70.7M | -10% |
| Q2 2025 | $78.2M | -14% |
| Q1 2025 | $69.6M | -15% |
| Q4 2024 | $83.5M | -14% |
SKIN's revenue has slid since its 2023 peak: $69M last quarter, down 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.2% | +16 points |
| Q2 2026 | 5% | +8.4 points |
| Q1 2026 | -2.8% | +15 points |
| Q4 2025 | 0.2% | +8.8 points |
| Q3 2025 | -8.8% | +19 points |
| Q2 2025 | -3.5% | +21 points |
| Q1 2025 | -17% | +3.6 points |
| Q4 2024 | -8.6% | +10 points |
SKIN's operating margin was 7.2% last quarter, up 16 points from the same quarter a year ago, near the top of its range since 2021.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over SKIN on cash flow, with more consistent year-over-year improvement.
SKIN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.2M | +16% |
| Q2 2026 | $2.2M | -77% |
| Q1 2026 | -$5.8M | -296% |
| Q4 2025 | $15.1M | -8.2% |
| Q3 2025 | $9.6M | -6.7% |
| Q2 2025 | $9.6M | +63% |
| Q1 2025 | $3M | +$20.1M |
| Q4 2024 | $16.4M | +$21.6M |
SKIN still generates free cash flow, though less than at its 2023 peak: $23M over the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SKIN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SKIN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +30.3K shares |
| 1 year | +2.6% | +166K shares |
| 3 years | -1.9% | -126K shares |
| 5 years | +1032% | +5.9M shares |
SKIN has 7M diluted shares, up 2.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | $30.2M |
| Q4 2022 | $80M |
| Q4 2021 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SKIN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.8x | Net Cash |
| Q2 2026 | -13.5x | Net Cash |
| Q1 2026 | -21.9x | Net Cash |
| Q4 2025 | -7,050.7x | Net Cash |
SKIN has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SKIN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.9 | Neutral |
| Stochastic | 58.5 | Neutral |
SKIN's weekly RSI is 54 (neutral) and its Stochastic is 59 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SKIN PE vs Healthcare Sector
SKIN has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
SKIN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.5 | 28% above |
| 20 week MA | $13.6 | 17% above |
| 50 week MA | $18.1 | 12% below |
| 100 week MA | $25.2 | 37% below |
| 200 week MA | $64.3 | 75% below |
SKIN has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over SKIN on returns for 2026, with the stronger performance.
SKIN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $204.2 | $223.0 | +9.2% |
| 2021 | $223.0 | $463.0 | +108% |
| 2022 | $463.0 | $180.8 | -61% |
| 2023 | $180.8 | $62.2 | -66% |
| 2024 | $62.2 | $32.4 | -48% |
| 2025 | $32.4 | $29.2 | -9.9% |
| 2026 YTD | $29.2 | $16.0 | -45% |
SKIN has finished four years in a row lower, and it's down 45% so far in 2026.